Twenty newly admitted acute schizophrenic patients were treated with haloperidol for 6 weeks. HVA and 5-HIAA were sampled at baseline, 3days after initial neuroleptic dose, and after 1, 2, 3, 4, 6 weeks of treatment. Nine patients were classified as responders in this prospective haloperidol treatment trial. They had a score of change in the BPRS total scores of 25% or greater. Eleven patients were classified as nonresponders, based on a score of changes in the BPRS total scores of less than 25%. 1) There was no significant difference in plasma HVA/5-HIAA ratio between responder and non-responder before and after haloperidol treatment. 2) There was no significant correlations between plasma HVA/5-HIAA ratio and BPRS total scores. This study could not support the hypothesis that neuroleptic treatment would be effective by changing dopamine and serotonin function and/or by altering their interaction.
Dopamine ; Haloperidol ; Humans ; Hydroxyindoleacetic Acid ; Plasma* ; Prospective Studies ; Schizophrenia* ; Serotonin

No abstract available.
Carbamazepine* ; Haloperidol*

No abstract available.
Dopamine Plasma Membrane Transport Proteins* ; Dopamine* ; Humans ; Pilot Projects* ; Tomography, Emission-Computed, Single-Photon*

Conventional neuroleptic treatment of organic delusional disorder can induce many serious side effects including extrapyramidal symptoms, sedation and tardive dyskinesia, especially in elderly patients. Risperidone is an atypical neuroleptics that is lack of severe extrapyramidal symptoms. This 68-year-old male case demonstrated that elderly patients with organic delusional disorder could be treated with risperidone without serious side effects.
Aged* ; Antipsychotic Agents ; Delusions* ; Humans ; Male ; Movement Disorders ; Risperidone* ; Schizophrenia, Paranoid*

No abstract available.

OBJECTIVE: The purpose of this study was to investigate the effect of clozapine on seam prolactin concentration in schizophrenic patients. METHOD: The subjects composed of 3-schizophrenic patients with hyperprolactinemia after treatment with risperidone and 9-tratment resistant chronic schizophrenic patients. Serum prolactin concentration was measured by radioimmunoassay method before clozapine administration and artier 1 and 4 week of treatment. Data were analysed by the SAS program. Statistical methods employed was Wilcoxon-sign rank test. RESULTS: 1) Clozapine had improving effect on 3 risperidone-induced hyperprolactinemic patients. 2) Clozapine did not have significant effect on serum prolactin levels in 9-tratment resistant chronic schizophrenic patients. CONCLUSION: Clozapine has minimal effects on serum prolactin levels in schizophrenic patients as well as improving effect on antipsychotics-induced hyperprolactinemia. We recommend atypical antipsychotics such as clozapine as alternative treatments for complicated hyperprolactinemia induced by other antipsychotics.
Antipsychotic Agents ; Clozapine* ; Humans ; Hyperprolactinemia ; Plasma* ; Prolactin* ; Radioimmunoassay ; Risperidone ; Schizophrenia

To assess the efficacy and safety of combining electroconvulsive therapy(ECT) and clozapine in patients with treatment-resistant schizophrenia, the authors reviewed use of this combination in one treatment-resistant schizophrenic inpatient and to explain the mechanism of this combination, we measured the blood level of clozapine and its metabolite with high performance liquid chromatography(HPLC) before, during and after this combination. The combination of clozapine and bilateral ECT was mildly effective and the authors saw no adverse effects during combined treatment. The blood levels of clozapine and its metabolite did not significant change before, during and afyer this combination. Combining ECT and clozapine appears to be safe and is effective without significant change of the blood levels of clozapine and its metabolites in some patients with treatment-resistant schizophrenia.
Clozapine* ; Electroconvulsive Therapy* ; Humans ; Inpatients ; Schizophrenia

This report describes the efficacy of combined use of aripiprazole in the treatment of a patient with clozapine induced enuresis. Aripiprazole acts as a potential dopamine partial agonist and the dopamine blockade in the basal ganglia might be one of the causes of urinary incontinence and enuresis. We speculate that aripiprazole functioned as a D2 agonist in hypodopaminergic state of basal ganglia caused by clozapine and maintained dopamine level that would improve enuresis ultimately.
Adult ; Antipsychotic Agents/*adverse effects ; Clozapine/*adverse effects ; Dopamine/metabolism ; Dopamine Agonists/*therapeutic use ; Drug Therapy, Combination ; Enuresis/chemically induced/*drug therapy ; Humans ; Male ; Middle Aged ; Piperazines/*therapeutic use ; Quinolones/*therapeutic use ; Schizophrenia, Paranoid/drug therapy

No abstract available.
Allopurinol* ; Alprostadil* ; Skin*

OBJECTIVES: Changes in plasma homovanillic acid(HVA) were investigated in neuroleptic responsive and non-responsive schizophrenics in order to delineate parameters of dopamine regulation, which may underlie differences in neuroleptic responsivity. METHOD: Twenty newly admitted acute schizophrenic patients were treated with haloperidol for 6 weeks. HVA was sampled at baseline, 3 days after initial neuroleptic dose, and after 1, 2, 3, 4, 6 weeks of treatment. Nine patients were classified as responders in this prospective haloperidol treatment trial. They had a score of change in the BPRS total scores of 25% or greater. Eleven patients were classified as nonresponders, based on a score of changes in the BPRS total scores of less than 25%. RESULTS: 1) The age of onset in respnder was older than nonresponder. 2) There were no significant changes in plasma HVA levels in total patients during 6 weeks haloperidol treatment period, but the nonreponders had a robust decrease in HVA level from baseline to 3 days and one week after haloperidol treatment in successive comparison. 3) There were no significant correlations between plasma HVA level and total scores of BPRS. CONCLUSIONS:This study suggested that neuroleptic non-responsive schizophrenics had a different plasma HVA concentration during haloperidol treatment but could not provide support to the idea that change in plasma HVA in response to neuroleptics can predict eventual clinical response to treatment. Further study is required in order to better characterize the changes in dopamine turnover in subgroups of schizophrenics.
Age of Onset ; Antipsychotic Agents ; Dopamine ; Haloperidol ; Homovanillic Acid* ; Humans ; Plasma* ; Prospective Studies ; Schizophrenia